EGFR and HER2 Expression in Papillary Thyroid Carcinoma

다국어 초록 (Multilingual Abstract)

Purpose: The epidermal growth factor receptor (EGFR) family plays a crucial role in the growth of malignant tumors. EGFR and human EGFR 2 (HER2) protein overexpression are associated with an unfavorable prognosis and are important therapeutic targets in breast cancer. The aim of this study was to evaluate the relationship between EGFR and HER2 expression and clinicopathological factors in papillary thyroid carcinoma (PTC) at a single institution.
Methods: A total of 129 consecutive patients with PTC were enrolled in this study and underwent thyroid surgery between October 2013 and February 2015. EGFR and HER2 protein expression was evaluated in the 129 primary tumors by immunohistochemistry, and the results were compared with the clinicopathological features.
Results: Of the 129 PTC tumors, 20 (15.5%) were HER2 positive, and 109 (84.5%) were HER2 negative. Moreover, EGFR positivity were observed in 111 (86%) tumors. The mean age of the patients was 46.3±11.9 years (range, 20–74 years), and the mean tumor size was 1.08±0.75 cm (range, 0.2–3.5 cm). Tumor size, extrathyroidal extension, histological subtype, and TNM stage were not significantly associated with EGFR or HER2 expression. Meanwhile, high Ki-67 labeling index was significantly associated with EGFR expression (P=0.002), HER2 expression was significantly associated with younger age (≤45 years) and cervical lymph node metastasis.
Conclusion: Based on our data, it is not clear whether EGFR and HER2 expression is associated with tumor aggressiveness in PTC.

참고문헌 (Reference)

1 Pellegriti G, "Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors" 2013 : 965212-, 2013

2 Sipos JA, "Thyroid cancer epidemiology and prognostic variables" 22 : 395-404, 2010

3 Kebebew E, "The prevalence and prognostic value of BRAF mutation in thyroid cancer" 246 : 466-470, 2007

4 Ross JS, "The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy" 3 : 237-252, 1998

5 Yan J, "Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis" 16 : 823-829, 2015

6 Freudenberg LS, "Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma" 44 : 179-182, 2005

7 Ito Y, "Prognostic significance of Ki-67 labeling index in papillary thyroid carcinoma" 34 : 3015-3021, 2010

8 Hay ID, "Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989" 114 : 1050-1057, 1993

9 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population" 연세대학교의과대학 45 (45): 818-821, 2004

10 Kjellman P, "MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma" 13 : 371-380, 2003

11 Luporsi E, "Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review" 132 : 895-915, 2012

12 Davies L, "Increasing incidence of thyroid cancer in the United States, 1973–2002" 295 : 2164-2167, 2006

13 Tang C, "High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma" 7 : 3213-3223, 2014

14 Ensinger C, "Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas" 23 : 2349-2353, 2003

15 Saha R, "Expression of phosphatase and tensin homolog, epidermal growth factor receptor, and Ki-67 in astrocytoma: a prospective study in a tertiary care hospital" 35 : 149-155, 2014

16 Mitrasinovic PM, "Epidermal growth factor receptors: a functional perspective" 5 : 29-33, 2012

17 Fisher KE, "Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma" 185 : 217-224, 2013

18 Arteaga CL, "Epidermal growth factor receptor dependence in human tumors: more than just expression" 7 (7): 31-39, 2002

19 Gori S, "EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab" 20 : 648-654, 2009

20 Nicholson RI, "EGFR and cancer prognosis" 37 (37): S9-S15, 2001

21 Tang W, "Differentiation, proliferation and retinoid receptor status of papillary carcinoma of the thyroid" 53 : 204-213, 2003

22 Verkooijen HM, "Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland" 14 : 13-17, 2003

23 Zhang XL, "Comparative study on overexpression of HER2/neu and HER3 in gastric cancer" 33 : 2112-2118, 2009

24 Kim KB, "Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation" 23 : 1277-1283, 2013

25 Kim YS, "Clinical predictors of right upper paraesophageal lymph node metastasis from papillary thyroid carcinoma" 10 : 164-, 2012

26 Tang KT, "BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications" 73 : 113-128, 2010

27 Rebaï M, "Association of EGFR and HER2 polymorphisms with risk and clinical features of thyroid cancer" 13 : 779-784, 2009

28 Sugishita Y, "Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening" 42 : 1589-1596, 2013

29 Wolff AC, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer" 25 : 118-145, 2007